MEDP vs. VRTX: Medpace vs. Vertex Pharmaceuticals Stock Comparison

Company Profile

Medpace (MEDP) and Vertex Pharmaceuticals (VRTX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while VRTX is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Vertex Pharmaceuticals (VRTX) at 20.80% also sits in the top quartile.

Both Medpace (MEDP) at 18.24% and Vertex Pharmaceuticals (VRTX) at 30.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Medpace (MEDP) at 23.12% and Vertex Pharmaceuticals (VRTX) at 35.57% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Medpace (MEDP) at 19.97% and Vertex Pharmaceuticals (VRTX) at 8.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; Vertex Pharmaceuticals (VRTX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Medpace (MEDP) at 0.83 and Vertex Pharmaceuticals (VRTX) at 2.34 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Medpace (MEDP) at 0.29 and Vertex Pharmaceuticals (VRTX) at 0.31 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Medpace (MEDP) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Medpace (MEDP) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both Medpace (MEDP) at 36.26 and Vertex Pharmaceuticals (VRTX) at 35.21 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both Medpace (MEDP) at 6.44 and Vertex Pharmaceuticals (VRTX) at 10.71 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: Vertex Pharmaceuticals (VRTX) at 6.63 sits in the upper P/B ratio quartile, and Medpace (MEDP) at 31.23 prices even higher, above its industry range.

Valuation Metrics